PTC Therapeutics, Inc.
$4.13B- Market cap
- $5.79B
- Debt
- +$286.63M
- Cash
- −$1.95B
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PTCT stock price vs ITCI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ITCI's multiple
Needs ITCI P/E.
Implied fair value · at PTCT's multiple
Needs EPS (TTM) is negative.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PTCT FY 2025 (ended Dec 31, 2025) · ITCI FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PTC Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Intra-Cellular Therapies, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-1.40x
0.19x
Net debt / EBITDA
Leverage against operating earnings
-2.21x
1.23x
Cash and equivalents
Liquid reserves on the balance sheet
$1.95B
$306.95M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
PTCT vs VRTX
Sarepta Therapeutics, Inc.
PTCT vs SRPT
BIOMARIN PHARMACEUTICAL INC
PTCT vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
PTCT vs ALNY
SUPERNUS PHARMACEUTICALS, INC.
PTCT vs SUPN
ACADIA PHARMACEUTICALS INC
PTCT vs ACAD
Vanda Pharmaceuticals Inc.
PTCT vs VNDA
Sage Therapeutics, Inc.
PTCT vs SAGE
$286.63M
$216.05M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.